112 related articles for article (PubMed ID: 32970300)
1. Examining the relationship between diabetes and prostate cancer through changes in screening guidelines.
Miller EA; Pinsky PF
Cancer Causes Control; 2020 Dec; 31(12):1105-1113. PubMed ID: 32970300
[TBL] [Abstract][Full Text] [Related]
2. Differences in the relationship between diabetes and prostate cancer among Black and White non-Hispanic men.
Miller EA; Pinsky PF; Pierre-Victor D
Cancer Causes Control; 2021 Dec; 32(12):1385-1393. PubMed ID: 34374921
[TBL] [Abstract][Full Text] [Related]
3. The relationship between diabetes, prostate-specific antigen screening tests, and prostate cancer.
Miller EA; Pinsky PF; Pierre-Victor D
Cancer Causes Control; 2018 Oct; 29(10):907-914. PubMed ID: 30094676
[TBL] [Abstract][Full Text] [Related]
4. Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11 year historical population follow-up study of more than 1 million men.
Dankner R; Boffetta P; Keinan-Boker L; Balicer RD; Berlin A; Olmer L; Murad H; Silverman B; Hoshen M; Freedman LS
Diabetologia; 2016 Aug; 59(8):1683-91. PubMed ID: 27189066
[TBL] [Abstract][Full Text] [Related]
5. Prostate Cancer Screening and Incidence among Aging Persons Living with HIV.
Leapman MS; Stone K; Wadia R; Park LS; Gibert CL; Goetz MB; Bedimo R; Rodriguez-Barradas M; Shebl F; Justice AC; Brown ST; Crothers K; Sigel KM
J Urol; 2022 Feb; 207(2):324-332. PubMed ID: 34555924
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
Buzzoni C; Auvinen A; Roobol MJ; Carlsson S; Moss SM; Puliti D; de Koning HJ; Bangma CH; Denis LJ; Kwiatkowski M; Lujan M; Nelen V; Paez A; Randazzo M; Rebillard X; Tammela TL; Villers A; Hugosson J; Schröder FH; Zappa M
Eur Urol; 2015 Nov; 68(5):885-90. PubMed ID: 25791513
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
[TBL] [Abstract][Full Text] [Related]
8. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
9. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
Schmanke K; Okut H; Ablah E
Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304
[TBL] [Abstract][Full Text] [Related]
10. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
11. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Leitzmann MF; Ahn J; Albanes D; Hsing AW; Schatzkin A; Chang SC; Huang WY; Weiss JM; Danforth KN; Grubb RL; Andriole GL;
Cancer Causes Control; 2008 Dec; 19(10):1267-76. PubMed ID: 18618278
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
13. Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States.
Nguyen DD; Trinh QD; Cole AP; Kilbridge KL; Mahal BA; Hayn M; Hansen M; Han PKJ; Sammon JD
Cancer; 2021 Jan; 127(2):249-256. PubMed ID: 33165954
[TBL] [Abstract][Full Text] [Related]
14. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
15. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.
Freedland SJ; Hamilton RJ; Gerber L; Banez LL; Moreira DM; Andriole GL; Rittmaster RS
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):254-9. PubMed ID: 23567655
[TBL] [Abstract][Full Text] [Related]
16. Optimal screening interval for men with low baseline prostate-specific antigen levels (≤1.0 ng/mL) in a prostate cancer screening program.
Urata S; Kitagawa Y; Matsuyama S; Naito R; Yasuda K; Mizokami A; Namiki M
World J Urol; 2017 Apr; 35(4):579-586. PubMed ID: 27421271
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Prostate Cancer by Opportunistic Screening in Korean Men with a Prostate-Specific Antigen Level Less Than 4.0 ng per Milliliter.
Choi H; Cho S; Bae JH; Lee SE; Hong SK; Moon DG; Cheon J; Byun SS; Park JY
Urol Int; 2017; 99(2):143-148. PubMed ID: 28395285
[TBL] [Abstract][Full Text] [Related]
18. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau).
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Wyler SF; Chun FF; Recker F; Kwiatkowski M
World J Urol; 2015 Aug; 33(8):1189-96. PubMed ID: 25358675
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
